Deals in Depth: August 2010
Executive Summary
Disclosed pre-commercial potential deal values in pharma alliances were on the low side in August - topping the list at only $80 million was Biogen Idec's license to Knopp's Phase II ALS candidate. Life Technologies gained more DNA sequencing tools through its $375 million buy of Ion Torrent Systems in a transaction that also includes $350 million in earn-outs. Pharma financing was up 20% from July, while device company fund-raising was down by more than half.